Cargando…

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss

Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB (RANK) ligand. The signaling pathway...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trouvin, Anne-Priscille, Goëb, Vincent
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010170/ https://www.ncbi.nlm.nih.gov/pubmed/21228900 http://dx.doi.org/10.2147/CIA.S10153

Ejemplares similares

Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease
por: Ugay, Ludmila, et al.
Publicado: (2016)

Osteoprotegerin/receptor activator of nuclear factor-κB ligand are involved in periodontitis-promoted vascular calcification
por: Jiao, Mengyu, et al.
Publicado: (2022)

Platelet-rich fibrin increases the osteoprotegerin/receptor activator of nuclear factor-κB ligand ratio in osteoblasts
por: Sumida, Ryuta, et al.
Publicado: (2019)

Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer
por: Elfar, Gamal A., et al.
Publicado: (2017)

Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients
por: Carmona-Fernandes, Diana, et al.
Publicado: (2011)

Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand in osteoblasts in vivo and in vitro
por: LI, JINGWU, et al.
Publicado: (2016)

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance
por: YU, XIUCHUN, et al.
Publicado: (2013)

The opioid epidemic: helping rheumatologists prevent a crisis
por: Trouvin, Anne-Priscille, et al.
Publicado: (2019)

“Ten-year mixed method evaluation of prelicensure health professional student self-reported learning in an interfaculty pain curriculum”: a view on pain education
por: Trouvin, Anne-Priscille
Publicado: (2022)

Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus
por: Lambrinoudaki, Irene, et al.
Publicado: (2013)

Increase in receptor activator of nuclear factor κB ligand/osteoprotegerin ratio in peri-implant gingiva exposed to Porphyromonas gingivalis lipopolysaccharide
por: Shuto, Takahiro, et al.
Publicado: (2016)

Imbalance of osteoprotegerin/receptor activator of nuclear factor-κB ligand and oxidative stress in patients with obstructive sleep apnea-hypopnea syndrome
por: Ma, Xiao-Rong, et al.
Publicado: (2019)

Receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in gingival crevicular fluid
por: Sarlati, Fatemeh, et al.
Publicado: (2012)

Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
por: Park, Hye-Rim, et al.
Publicado: (2003)

Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study
por: Lien, Gunhild, et al.
Publicado: (2010)

Functional and histological improvements of small nerve neuropathy after high-concentration capsaicin patch application: A case study
por: Trouvin, Anne-Priscille, et al.
Publicado: (2019)

Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis
por: Giaginis, Constantinos, et al.
Publicado: (2012)

Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in human osteoblasts
por: ZHANG, YUANYU, et al.
Publicado: (2015)

Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health
por: Tabari, Zahra Alizadeh, et al.
Publicado: (2013)

Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease
por: Mizuno, Manami, et al.
Publicado: (2015)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
por: Widschwendter, Martin, et al.
Publicado: (2015)

Effect of Breastfeeding on Serum Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Kappa B Ligand in Full Term Neonates
por: Rafeey, Mandana, et al.
Publicado: (2013)

The Role of Osteoprotegerin and Its Ligands in Vascular Function
por: Rochette, Luc, et al.
Publicado: (2019)

Three dimensions of pain in osteoarthritis: development and validation of the Osteoarthritis Symptom Inventory Scale
por: Perrot, Serge, et al.
Publicado: (2023)

Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease
por: Pacifico, Lucia, et al.
Publicado: (2018)

Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling
por: Zhang, Luodan, et al.
Publicado: (2022)

Osteoprotegerin protects from generalized bone loss in TNF-transgenic mice
por: Hayer, S, et al.
Publicado: (2003)

Production of Soluble Receptor Activator of Nuclear Factor Kappa-Β Ligand and Osteoprotegerin by Apical Periodontitis Cells in Culture and Their Modulation by Cytokines
por: Duka, Miloš, et al.
Publicado: (2019)

Effects of alpha-calcitonin gene-related peptide on osteoprotegerin and receptor activator of nuclear factor-κB ligand expression in MG-63 osteoblast-like cells exposed to polyethylene particles
por: Xu, Jie, et al.
Publicado: (2010)

A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin
por: Xiong, Jing, et al.
Publicado: (2022)

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
por: Burgess, Teresa L., et al.
Publicado: (1999)

Prolactin blocks the expression of receptor activator of nuclear factor κB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis
por: Ledesma-Colunga, Maria G., et al.
Publicado: (2017)

Bone Loss, Osteoporosis, and Fractures in Patients with Rheumatoid Arthritis: A Review
por: Fardellone, Patrice, et al.
Publicado: (2020)

Effects of High and Low Doses of Folic Acid on the Soluble Receptor Activator of Nuclear Factor-kappa B Ligand/Osteoprotegerin Ratio during Pregnancy
por: FATHI MAROUFI, Nazila, et al.
Publicado: (2017)

Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort
por: Sarink, Danja, et al.
Publicado: (2018)

Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2016)

IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand
por: Guerra-Menéndez, Lucia, et al.
Publicado: (2013)

Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
por: Vachliotis, Ilias D., et al.
Publicado: (2023)

RANK, RANKL and osteoprotegerin in bone biology and disease
por: Wright, H. L., et al.
Publicado: (2009)

Osteoprotegerin in Bone Metastases: Mathematical Solution to the Puzzle
por: Ryser, Marc D., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e1g784mjtk14i9e2g5ourh98c2